China-Based Biotech Selects Medidata Platform

March 24, 2016

Henlius Biotechnology has selected Medidata’s Medidata Clinical Cloud® platform for its Phase III oncology clinical trial in China.

China-based Shanghai Henlius Biotechnology Co. Ltd. (Henlius) has selected Medidata’s Medidata Clinical Cloud® platform, specifically Medidata Rave® (electronic data capture) and Medidata Balance® (randomization and trial supply management) in its Phase III oncology clinical trial in China.

 

Henlius focuses on the development, production and commercialization of monoclonal antibody drugs for a number of therapeutic areas, including oncology and auto-immune diseases.

 

Read the full release.

 

Related Content:

News